Abstract
The Y box-binding protein 1 (YB-1) is a multifunctional DNA/RNA-binding protein regulating transcriptional and translational processes. Emerging evidence suggests a role for YB-1 in malignant human disease. Protein expression levels of YB-1 are increased in numerous human cancers, and nuclear YB-1 correlates with poor prognosis of tumor patients. However, YB-1 has also anti-oncogenic activities and interferes with phosphoinositide 3-kinase dependent cellular transformation. The anti-oncogenic activity correlates with cytoplasmic localization and with inhibition of protein synthesis. This review seeks to highlight the transcriptional and translational functions of YB-1 and its role in oncogenesis.
Current Cancer Therapy Reviews
Title: YB-1 Activities in Oncogenesis: Transcription and Translation
Volume: 2 Issue: 1
Author(s): Andreas G. Bader
Affiliation:
Keywords: Y box, DbpB, p50, NSEP-1, EF-IA, mRNP
Abstract: The Y box-binding protein 1 (YB-1) is a multifunctional DNA/RNA-binding protein regulating transcriptional and translational processes. Emerging evidence suggests a role for YB-1 in malignant human disease. Protein expression levels of YB-1 are increased in numerous human cancers, and nuclear YB-1 correlates with poor prognosis of tumor patients. However, YB-1 has also anti-oncogenic activities and interferes with phosphoinositide 3-kinase dependent cellular transformation. The anti-oncogenic activity correlates with cytoplasmic localization and with inhibition of protein synthesis. This review seeks to highlight the transcriptional and translational functions of YB-1 and its role in oncogenesis.
Export Options
About this article
Cite this article as:
Bader G. Andreas, YB-1 Activities in Oncogenesis: Transcription and Translation, Current Cancer Therapy Reviews 2006; 2 (1) . https://dx.doi.org/10.2174/157339406775471786
DOI https://dx.doi.org/10.2174/157339406775471786 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Transfer of DNA Encoding Adenoviral E1A
Recent Patents on Anti-Cancer Drug Discovery The Vitamin D/CYP24A1 Story in Cancer
Anti-Cancer Agents in Medicinal Chemistry RECKing MMP: Relevance of Reversion-inducing Cysteine-rich Protein with Kazal Motifs as a Prognostic Marker and Therapeutic Target for Cancer (A Review)
Anti-Cancer Agents in Medicinal Chemistry Mesenchymal Stem Cells Derived from Wharton's Jelly of the Umbilical Cord: Biological Properties and Emerging Clinical Applications
Current Stem Cell Research & Therapy Conditionally Replicating Adenoviruses for Cancer Treatment
Current Cancer Drug Targets Mesenchymal Stem Cells Promote Caspase Expression in Molt-4 Leukemia Cells <i>Via</i> GSK-3α/Β and ERK1/2 Signaling Pathways as a Therapeutic Strategy
Current Gene Therapy Therapeutic Potential and Pharmaceutical Applications of <i>Cucurbita</i>
Current Nutrition & Food Science MicroRNA Regulation of TRAIL in Renal Carcinoma: Tiny Juggernauts at Work
Current Molecular Pharmacology Decreased lncRNA SNHG16 Accelerates Oxidative Stress Induced Pathological Angiogenesis in Human Retinal Microvascular Endothelial Cells by Regulating miR-195/mfn2 Axis
Current Pharmaceutical Design A Review on Exploring Better Safety Prospects in Managing Cancer using Liposomal Combinations of Food Bioactive Compounds and Anticancer Drugs: Combisomes
Current Drug Delivery Serum Amyloid A and Its Potential Physiological / Pathological Functions - an Overview of Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Targeting Antioxidants to Mitochondria: A Potential New Therapeutic Strategy for Cardiovascular Diseases
Current Pharmaceutical Design Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets Nanoparticles based on oleate alginate ester as curcumin delivery system
Current Drug Delivery Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication
Current Drug Metabolism Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials
Current Pharmaceutical Design Hollow Inorganic Nanoparticles as Efficient Carriers for siRNA Delivery: A Comprehensive Review
Current Pharmaceutical Design TRIM65 in White Matter Lesions, Innate Immunity, and Tumor
Current Molecular Pharmacology Nanostructured Systems for the Organelle-specific Delivery of Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Nanomedicine as a Strategy for Natural Compound Delivery to Prevent and Treat Cancers
Current Pharmaceutical Design